Learned clinical and genetic features classify radiation pneumonitis in a small cohort
Source check: Source checked. Not independent scientific confirmation.
Finding: Learned feature selection and classifiers evaluated radiation-pneumonitis outcomes in 59 lung-cancer patients. A four-variable set combining clinical, treatment-volume and genetic information yielded a reported XGBoost AUC of 0.815 in repeated internal evaluation. This is exploratory cohort validation, without an independently tested pretreatment risk tool or demonstrated treatment benefit.
Technology: LASSO; recursive feature elimination; XGBoost; random forest; support-vector machine
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Learned regularized feature selection and classifiers link measured clinical/genetic inputs to recorded pneumonitis outcomes, supporting the bounded retrospective evaluation.
- Test and result
- Prospectively collected 2017-2019 cohort data were analyzed using internal nested cross-validation and training-fold oversampling. The endpoint was grade2-or-higher radiation pneumonitis, occurring in about20% of59 patients.
- Limitation / still unknown
- Prospective collection does not establish a locked prospective predictor. Final features were aggregated across folds before another evaluation, so full selection-pipeline isolation is not established. Model/feature-set choice reused the same small cohort; no external or cross-ethnicity validation, causal genetic mechanism or clinical benefit was demonstrated. Supplementary details and operational laboratory procedures were not independently reviewed.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11332843/ · https://doi.org/10.1016/j.ctro.2024.100819
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 21 Nov 2026. Review scope: Exact primary front, clinical cohort/endpoint, computational feature-selection/classifier Methods, Results and limitations; operational genotyping procedures not inspected.
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.